LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Developing 'Lab-in-Box' Kit for Medium Throughput Processing of COVID-19 Samples for Detection Using RT-PCR

By LabMedica International staff writers
Posted on 10 Nov 2020
Illustration
Illustration
A team of scientists is developing viral RNA extraction kits for medium-throughput processing of COVID-19 samples for detection using RT-PCR.

Magnostics Ltd. (Dublin, Ireland) is leading a consortium of scientists to develop and launch viral RNA extraction kits for the detection of COVID-19. To detect the SARS-CoV-2 virus, which causes COVID-19 infection, a very small number of RNA viral genomes must be isolated from the nasal swab. This is a stereotypical needle in the haystack problem where there are a very small number of viruses among tens of thousands of much larger cells. The team of scientists has developed necessary protocols for SARS-cov-2 testing based on Magnostics' Si@Hi-Mag superparamagnetic beads. The key is to use Si@Hi-mag magnetic nanoparticles to capture the RNA from the complicated soup that makes up the virus lysate, which includes proteins, lipids, and other cellular components, and then use a powerful magnet to move and thus separate the magnetic nanoparticles. This allows a series of solutions to be used to rinse the RNA-nanoparticle complex and then release the RNA into a buffer that can be used for reverse transcription and quantitative detection with the polymerase chain reaction (PCR).

Using test samples from patients, the team has proven that Si@Hi-mag beads can be used to extract viral RNA from clinical samples. This includes Lysis buffer, which inactivates and bursts open the virus, superparamagnetic nanoparticles, and a rare-earth magnet array for medium-throughput processing. This important demonstration forms the basis for Magnostics to develop a CE marked 'lab-in-box' kit for the medium throughput manual extraction of viral RNA from clinical samples. The product will allow clinical laboratories to perform 400-600 extractions per day using existing infrastructure.

Related Links:
Magnostics Ltd.

Gold Member
SARS-CoV-2 PCR Test
Macurra SARS-CoV-2 PCR Kit
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter

Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
PURITAN MEDICAL